Abstract: Epithelial growth factor receptor(EGFR) plays an important role in numerous cancers and many types of targeting EGFR drugs have been approved by the Food and Drug Administration. However, the individual sensitivity and efficiency rates of these targeting EGFR medicines are low. Many studies have shown that patients with high EGFR expression or mutation are responsive to targeting drugs. Therefore, clearing the EGFR expression and mutation status is significant for clinical medication. PET is a noninvasive in vivo imaging technique that enables the visualization and quantification of the distribution of molecules labeled with positron-emitting isotopes at a picomolar level. PET can guide the precision medicine for these targeting EGFR drugs. This review summarizes the small-molecule PET probes for targeting EGFR.